This is a review article. Review articles usually do not publish new data; instead, they review and synthesize information from previously published articles. I haven’t read the whole thing yet, but I skimmed through it. This article provides background on the biology of Clever-1 and the rationale for Bexmarilimab combination therapies. Additionally, it presents, among other things, Clever-1 expression in different cancer types and the immunological state of tumors (in Figure 3 below). This is very relevant information for assessing Bex’s target market in solid tumors and is likely an important topic in partnership negotiations.
For example, based on this diagram, one can already get a much better assessment of the cancers that would most likely benefit from Bex treatment. C4 (red) is a potentially Bex-benefiting immune subtype, as it is a lymphocyte-depleted tumor environment, and previous Matins and Bexmab trials have shown Bex treatment leading to T-cell accumulation in the tumor after treatment. C3, on the other hand, could be tricky if that inflammatory environment is associated with high IFN-gamma levels, which causes the tumor macrophages to not react to Bex in the desired way. Furthermore, the targeted cancers must inherently be Clever-1 positive, meaning the cancers found on the right side of the table are unlikely to be good candidates for Bex treatments.
edit: abbreviations for the cancers in the image
UVM (uveal melanoma)
GBM (glioblastoma multiforme)
THCA (thyroid carcinoma)
KIRP (kidney renal papillary cell carcinoma)
PCPG (pheochromocytoma and paraganglioma)
KIRC (kidney renal clear cell carcinoma)
ACC (adrenocortical carcinoma)
PRAD (prostate adenocarcinoma)
LIHC (liver hepatocellular carcinoma)
KICH (kidney chromophobe)
CHOL (cholangiocarcinoma)
SARC (sarcoma)
LUAD (lung adenocarcinoma)
PAAD (pancreatic adenocarcinoma)
MESO (mesothelioma)
SKCM (skin cutaneous melanoma)
LGG (brain lower grade glioma)
BRCA (breast invasive carcinoma)
OV (ovarian serous cystadenocarcinoma)
BLCA (bladder urothelial carcinoma)
STAD (stomach adenocarcinoma)
UCEC (uterine corpus endometrial carcinoma)
ESCA (esophageal carcinoma)
READ (rectum adenocarcinoma)
LUSC (lung squamous cell carcinoma)
COAD (colon adenocarcinoma)
UCS (uterine carcinosarcoma)
TGCT (testicular germ cell tumors)
CESC (cervical squamous cell carcinoma and endocervical adenocarcinoma)
HNSC (head and neck squamous cell carcinoma)